Study of two drugs for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of two drugs, pasritamig and JNJ-86974680, for men with a certain type of advanced prostate cancer that has spread to bone or lymph nodes but not to organs like the lungs or liver. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of prostate cancer called adenocarcinoma (the most common kind).
- Your cancer has spread to bone or lymph nodes but not to major organs like the lungs or liver.
- You are on hormone therapy (like Lupron) or have had your testicles removed to lower testosterone.
- Your PSA level is 2 or higher at the start of the study.
- You are in good overall health with a performance status of 0 or 1 (able to do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
This study tests a new drug called JNJ-98768111 in people with advanced prostate cancer that has spread and is no longer responding to current hormone-based treatments. It aims to see if the drug is safe and effective, and participants will receive the study drug while continuing some standard hormone therapy.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
This trial tests an experimental drug (JNJ-101556143) for men with metastatic prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can slow down or stop the cancer from growing.
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
This study tests a new combination therapy for advanced prostate cancer that has stopped responding to standard treatments. It aims to see if the combination is more effective than placebo in slowing the cancer's growth.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.